5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine and Lymphoma--Primary-Effusion

5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine has been researched along with Lymphoma--Primary-Effusion* in 1 studies

Other Studies

1 other study(ies) available for 5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine and Lymphoma--Primary-Effusion

ArticleYear
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    mBio, 2019, 02-19, Volume: 10, Issue:1

    Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV). PEL has a highly active mTOR pathway, which makes mTOR a potential therapeutic target. MLN0128 is an ATP-competitive inhibitor of mTOR that has entered clinical trials for solid tumors. Our results demonstrated that MLN0128 has a greater effect on inhibiting proliferation than the allosteric mTOR inhibitor rapamycin. MLN0128 has ∼30 nM 50% inhibitory concentration (IC

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Benzoxazoles; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Heterografts; Humans; Inhibitory Concentration 50; Lymphoma, Primary Effusion; Mice; Neoplasm Transplantation; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome

2019